Information Provided By:
Fly News Breaks for February 27, 2020
ABBV
Feb 27, 2020 | 07:06 EDT
Barclays analyst Carter Gould initiated coverage of AbbVie with an Equal Weight rating and $97 price target as he sees a balanced/risk reward given he believes the current share price reflects stronger contributions from key growth assets and almost double-digit Humira U.S. demand growth in the near-term.